Menactra Vaccine, a vaccine against four types of bacteria that cause meningitis and the blood infection meningococcemia, has been recommended by the CDC (Centers for Disease Control and Prevention) for young people from 11 years old to college age. The vaccine has been used for a little over a year, but the FDA (Food and Drug Administration) and CDC issued a press release on September 30, 2005 and an alert on October 10, 2005 asking for information linking the use of Menactra Vaccine with Guillain Barre Syndrome (GBS), a serious neurological disorder. Five cases of GBS had been reported as occurring after administration of the Menactra Vaccine.
Menactra Vaccine is still in use and no interruption of the vaccination schedule has been recommended, but the FDA and CDC are investigating the possibility that the vaccine could be connected to GBS. They will continue to monitor the use of the vaccine to determine if GBS is a Menactra Vaccine side effect. The number of cases of GBS that have occurred so far could have been coincidental, but the correlation with the use of Menactra Vaccine and the seriousness of GBS call for immediate attention. The FDA and CDC have asked the public and health care providers to inform them about any links between GBS and the Menactra Vaccine. The manufacturer, Sanofi Pasteur, has pledged to work with the FDA and CDC to investigate any connection between the Menactra Vaccine and GBS.
No cases have yet been reported seeking damages because of a claim that the Menactra Vaccine caused GBS, most likely because Menactra Vaccine information is still being gathered. The situation is being monitored by pharmaceutical litigation law firms.
Check out the following articles for more information about Menactra Vaccine, filing a Menactra Vaccine lawsuit and finding a Menactra Vaccine attorney.
To learn more about dangerous drugs and the law, go to FreeAdvice.com.